Contact
Please use this form to send email to PR contact of this press release:
Orphan designation: Brentuximab vedotin Treatment of cutaneous T-cell lymphoma, 11/01/2012 Withdrawn
TO:
Please use this form to send email to PR contact of this press release:
Orphan designation: Brentuximab vedotin Treatment of cutaneous T-cell lymphoma, 11/01/2012 Withdrawn
TO: